Endocrine and bone
Bisphosphonates
Pyrophosphate analogues that bind bone mineral and are taken up by osteoclasts, inhibiting bone resorption: the first-line drugs for osteoporosis, and used for bone metastases and hypercalcaemia.
Mechanism of action
- They bind hydroxyapatite on bone surfaces, especially where bone is being remodelled.
- Osteoclasts take them up while resorbing bone; nitrogen-containing bisphosphonates inhibit farnesyl pyrophosphate synthase in the mevalonate pathway.
- Osteoclasts lose function and die by apoptosis: resorption falls, bone density rises and fractures decrease.
- They stay bound in bone for years.
Molecular targets
- Farnesyl pyrophosphate synthase in osteoclasts: Inhibitor
Drugs in Bisphosphonates
- Alendronate (By mouth, weekly.)
- Risedronate
- Ibandronate
- Zoledronic acid (Intravenous, yearly for osteoporosis.)
Therapeutic uses
- Postmenopausal, male and glucocorticoid-induced osteoporosis
- Bone metastases and myeloma (zoledronic acid)
- Hypercalcaemia of malignancy
- Paget disease of bone
- Preventing bone loss with aromatase inhibitors or androgen deprivation
Diseases it treats
Pharmacokinetics
- Very poorly absorbed: oral tablets are taken fasting, with plain water, upright for 30 minutes.
Adverse effects
- Oesophagitis and oesophageal ulcers (oral)
- Acute-phase reaction with fever and aches (intravenous)
- Osteonecrosis of the jaw (rare)
- Atypical femoral fractures with long use (rare)
- Hypocalcaemia
Contraindications by condition
- Oesophageal stricture or inability to stay upright (oral) (Contraindicated): Tablets lodging in the oesophagus cause ulcers.
- Hypocalcaemia (Contraindicated): It must be corrected first: they lower calcium further.
- Severe kidney impairment (Contraindicated): They are excreted by the kidney and can damage it.
- Peptic ulcer disease (Use with care): They irritate the upper gastrointestinal tract.
Connected topics
Written from
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 27, Drugs Affecting Bone Metabolism, Bisphosphonates
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 42, Agents That Affect Bone Mineral Homeostasis, Bisphosphonates
Educational reference. Not medical advice, diagnosis or treatment.